PT966968E - Combinacoes terapeuticas compreendendo um modulador de receptor de estrogenio selectivo e prostaglandina e2 - Google Patents
Combinacoes terapeuticas compreendendo um modulador de receptor de estrogenio selectivo e prostaglandina e2Info
- Publication number
- PT966968E PT966968E PT99304374T PT99304374T PT966968E PT 966968 E PT966968 E PT 966968E PT 99304374 T PT99304374 T PT 99304374T PT 99304374 T PT99304374 T PT 99304374T PT 966968 E PT966968 E PT 966968E
- Authority
- PT
- Portugal
- Prior art keywords
- prostaglandine
- comprehending
- compositions
- estrogen receptor
- receptor modulator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8946898P | 1998-06-16 | 1998-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT966968E true PT966968E (pt) | 2004-08-31 |
Family
ID=22217815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT99304374T PT966968E (pt) | 1998-06-16 | 1999-06-04 | Combinacoes terapeuticas compreendendo um modulador de receptor de estrogenio selectivo e prostaglandina e2 |
Country Status (10)
Country | Link |
---|---|
US (1) | US6284773B1 (pt) |
EP (1) | EP0966968B1 (pt) |
JP (1) | JP2000026298A (pt) |
AT (1) | ATE265853T1 (pt) |
BR (1) | BR9904146A (pt) |
CA (1) | CA2274381C (pt) |
DE (1) | DE69916932T2 (pt) |
DK (1) | DK0966968T3 (pt) |
ES (1) | ES2220005T3 (pt) |
PT (1) | PT966968E (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1353649A2 (en) * | 2000-12-21 | 2003-10-22 | Oscar M. Bassinson | Personal medication dispensing card |
WO2003011282A1 (en) | 2001-07-31 | 2003-02-13 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
KR102173464B1 (ko) | 2016-12-01 | 2020-11-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
US6124314A (en) * | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
-
1999
- 1999-06-04 AT AT99304374T patent/ATE265853T1/de not_active IP Right Cessation
- 1999-06-04 PT PT99304374T patent/PT966968E/pt unknown
- 1999-06-04 ES ES99304374T patent/ES2220005T3/es not_active Expired - Lifetime
- 1999-06-04 DE DE69916932T patent/DE69916932T2/de not_active Expired - Fee Related
- 1999-06-04 DK DK99304374T patent/DK0966968T3/da active
- 1999-06-04 EP EP99304374A patent/EP0966968B1/en not_active Expired - Lifetime
- 1999-06-14 CA CA002274381A patent/CA2274381C/en not_active Expired - Fee Related
- 1999-06-14 JP JP11167503A patent/JP2000026298A/ja active Pending
- 1999-06-16 BR BR9904146-4A patent/BR9904146A/pt not_active Application Discontinuation
- 1999-07-14 US US09/314,371 patent/US6284773B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2220005T3 (es) | 2004-12-01 |
ATE265853T1 (de) | 2004-05-15 |
EP0966968B1 (en) | 2004-05-06 |
DE69916932D1 (de) | 2004-06-09 |
EP0966968A1 (en) | 1999-12-29 |
CA2274381C (en) | 2004-02-10 |
DK0966968T3 (da) | 2004-08-30 |
US6284773B1 (en) | 2001-09-04 |
BR9904146A (pt) | 2000-05-09 |
CA2274381A1 (en) | 1999-12-16 |
JP2000026298A (ja) | 2000-01-25 |
DE69916932T2 (de) | 2005-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9714155A (pt) | Prevenção da perda e reposição da massa óssea por certos agonistas de prostaglandina. | |
BR9813028A (pt) | Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos | |
YU7797A (sh) | Kombinovana terapija za osteoporozu | |
BR9804437A (pt) | Compostos para a osteoporose | |
BR9710988A (pt) | Método e compostos moduladores receptores de androgênio | |
AP9801269A0 (en) | Prostaglandin agonists. | |
BR9510486A (pt) | Compostos moduladores de receptores de esteróide e métodos | |
NO20040331L (no) | Legemidler for sykdommer med benmassetap som har Eragonist som den aktive bestanddel | |
YU75800A (sh) | Terapeutske kombinacije koje sadrže modulator selektivnog estrogen receptora i paratiroidni hormon | |
PT966968E (pt) | Combinacoes terapeuticas compreendendo um modulador de receptor de estrogenio selectivo e prostaglandina e2 | |
BR9911324A (pt) | Combinações terapêuticas de moduladores de receptor (seletivo) de estrogênio (serm) e secretagogos de hormÈnio do crescimento (ghs) para o tratamento de fragilidade músculo-esqueletal | |
BR9811819A (pt) | 2-acilaminopropanaminas como antagonistas receptores de taquicinina | |
ECSP982698A (es) | Agonistas de prostaglandinas | |
ECSP982554A (es) | Agonistas de prostaglandinas | |
ATE262538T1 (de) | Lhrh-analoga zur behandlung der osteoporose | |
UY26651A1 (es) | Terapia combinada para la osteoporosis | |
ECSP993016A (es) | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratoroidea |